AnaptysBio, Inc.
ANAB Healthcare Biotechnology
AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024. In the quarter to March 2026, revenue fell 7.98%, EPS fell 43.8% and free cash flow fell 141.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow ANAB
AnaptysBio, Inc. (ANAB) Altman Z-score
AnaptysBio, Inc.'s Altman Z-score for fiscal 2025 is 0.84, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 0.84 | 2.31 |
| FY2024 | −1.47 | (0.02) |
| FY2023 | −1.45 | (1.64) |
| FY2022 | 0.19 | (1.25) |
| FY2021 | 1.44 | (10.60) |
| FY2020 | 12.03 | 6.83 |
| FY2019 | 5.20 | (22.76) |
| FY2018 | 27.96 | (8.87) |
| FY2017 | 36.84 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.86 | — | 1.03 | |
| Retained earnings / total assets | (2.12) | — | −2.97 | |
| EBIT / total assets | 0.13 | — | 0.43 | |
| Market value of equity / total liabilities | 2.84 | — | 1.70 | |
| Sales / total assets | 0.64 | — | 0.64 | |
| Altman Z-score | Distress zone | 0.84 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −0.30 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ABSI Absci Corporation compare | 5.5× |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | 1.5× |
| ANAB AnaptysBio, Inc. | 0.8× |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | 0.8× |
| QURE uniQure N.V. compare | −0.8× |
| RARE Ultragenyx Pharmaceutical Inc. compare | −3.6× |
| KRSA Korsana Biosciences, Inc. compare | −36.3× |
| RAPP Rapport Therapeutics, Inc. compare | — |
| MAZE Maze Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets